Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARS

Clasificación en acciones #4650
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Precio por acción
$69.68
Última sincronización: 2026-10-19
Capitalización bursátil
$3.26B
Cambio (1 día)
2.36%
Cambio (1 año)
-2.13%
País
US
Comercio Tarsus Pharmaceuticals, Inc. (TARS)

Categoría

Healthcare
Historial de dividendos de Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (símbolo bursátil: TARS) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Tarsus Pharmaceuticals, Inc. (TARS) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL